Kiran Mazumdar-Shaw Net Worth

Kiran Mazumdar-Shaw has an estimated net worth of $2.9 billion, according to Forbes Real-Time Billionaires, Kiran Mazumdar-Shaw profile (figures as of October 20, 2026). That is down from a peak of $4 billion.

Kiran Mazumdar-Shaw is an Indian entrepreneur best known for founding Biocon in 1978. She serves as executive chairperson of Biocon Limited and Biocon Biologics Limited. Biocon began with enzymes and later grew into a biopharmaceutical business. The company entered the U.S. market and also built one of Asia's largest insulin factories in Johor, Malaysia. Her wealth is tied to biopharmaceuticals, a field where Forbes classifies her in healthcare and as self-made.

Her path into business started after she wanted to study medicine but could not get into medical school. She then trained in malting and brewing in Australia, where she was the only woman in the brewing course in 1974 and topped her class. After brewery roles in Australia and India between 1975 and 1977, she shifted course. A meeting with Biocon Biochemicals led her to start Biocon India and build a company from a small Bengaluru base.

How Kiran Mazumdar-Shaw built her wealth

Most of Mazumdar-Shaw's fortune comes from the businesses she founded and led in biotechnology. Biocon India started in 1978 as an enzymes venture. Over time, she pushed it toward biopharmaceuticals, with work in diabetes, oncology and auto-immune diseases. She also set up Syngene in 1994 and Clinigene in 2000, later combining Clinigene with Syngene. In 2004, Biocon went public, giving the company a bigger base to fund research and expansion.

Biocon's later deals show where much of the value sits today. In 2022, Biocon Biologics bought the biosimilars business of Viatris for $3.3 billion. In December 2025, Biocon said it would buy the rest of privately held Biocon Biologics, valuing that business at $5.5 billion. Another related asset also gained attention when Biocon-backed Bicara Therapeutics raised $362 million in a Nasdaq IPO in 2024.

What Forbes says about her net worth

Forbes has tracked her wealth through several swings. It estimated her net worth at $3.5 billion in 2019, then $2.6 billion in 2020, before rising to $4 billion in 2021. Those changes came as Biocon kept expanding from its original enzymes business into larger drug markets. Forbes also classifies her as self-made, which fits the long arc from founder to biotech executive with global operations.

The estimate moved again later in the decade. Forbes put her at $2.1 billion in 2023, then $2.7 billion in 2024, $3.1 billion in 2025, and $3.5 billion in 2026. As of October 20, 2026, Forbes' real-time tracker shows $2.9 billion. We track that latest figure because her wealth is closely linked to Biocon, Biocon Biologics, and the value investors place on their drug businesses and deals.